fda semaglutide warning news october 2025 The U.S. health regulator asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. https://cnn.it/49uSrKw FDA issued 25 warning letters

Drawing from the STEP clinical trials, which showed significant weight reduction over 68 weeks, we understand that consistency is the key to longevity

The dose escalation protocolstarting at 3 mg for 30 days, then increasing to 7 mg, and potentially to 14 mg after another 30 daysmeans that patients may not reach their therapeutic dose until 8 to 12 weeks into treatment

Varios estudios han demostrado que las mujeres con SOP que utilizan agonistas del receptor GLP-1 experimentan mayores mejoras en la regularidad menstrual y en las tasas de ovulacin en comparacin con aquellas que dependen nicamente de cambios en el estilo de vida

Where GLP-1 and GIP work mostly on the input side (eating less, feeling full sooner, processing food differently), glucagon works on the output side (burning more energy and clearing fat from the liver)